Skip to main content
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Cancer Res. 2018 May 16;78(14):3823–3833. doi: 10.1158/0008-5472.CAN-17-3564

Figure 4. PYGO2 is amplified in PCa and correlates with higher Gleason score and metastasis.

Figure 4.

A, Frequency of PYGO2 copy number gain and amplification in a variety of PCa genomics datasets categorized by disease site and treatment. B, Fraction of PYGO2 copy number status in different Gleason score categories in the TCGA dataset. C, Correlation of PYGO2 copy number status with disease-free survival (n=329) or biochemical recurrence (n=281) in the TCGA dataset. D, PYGO2 mRNA expression level in primary tumor and metastasis in 4 PCa studies with data compiled from Oncomine. E, In the TMA, PYGO2 expression as measured by immunohistochemistry and plotted against Gleason grade categories. F, In an archived PCa clinical cohort from MD Anderson Cancer Center, PYGO2 expression plotted against categories as normal prostate, primary prostate tumor, lymph node (LN) metastases and bone metastases.